In this regard, LRRK2 is considered a priority therapeutic target for both forms of PD, familial and idiopathic since genetic, molecular, and pre-clinical studies support the involvement of LRRK2 in the pathophysiology of PD, with a missense mutation in LRRK2 being the most common cause of familial PD and common LRRK2 variants acting as risk factors for idiopathic PD (Klein and Westenberger, 2012). This evidence concerns the gene LRRK2 and Parkinson disease.